Navid Zaidi, MD
Pulmonary Disease · Joplin, MONPI 1700980232
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,437 of the $25,040 with a category attached, or 81.6%. Mylan Specialty L.p. accounts for 94.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $22,374 and has fallen 99.2% since, to $173 in 2025.
Across 70 payments — averaging $357.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$24K
- GSK$328
- Boehringer Ingelheim$236
- AstraZeneca$129
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Verona Pharma, Inc.$122
- plus $422 from 7 others
What the payments were for
- Speaking & faculty fees$20,43782%
- Travel & lodging$2,65811%
- Food & beverage$1,8327%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 51 | $23,678 |
| GSK | 4 | $328 |
| Boehringer Ingelheim | 2 | $236 |
| AstraZeneca | 3 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Verona Pharma, Inc. | 1 | $122 |
| Shire North American Group Inc | 1 | $90 |
| Actelion Pharmaceuticals US, Inc. | 1 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $81 |
| United Therapeutics Corporation | 2 | $73 |
| Genentech USA, Inc. | 1 | $40 |
| Abiomed | 1 | $36 |
| Ceribell, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,040 in reported general payments places this provider in the 85th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 24 | $130,298 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $82,034 |
| Dupixent PenDupilumab | 20 | $76,459 |
| XolairOmalizumab | 11 | $60,938 |
| Dupixent SyringeDupilumab | 11 | $48,423 |
| Spiriva RespimatTiotropium Bromide | 46 | $29,173 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $27,469 |
| Spiriva HandihalerTiotropium Bromide | 24 | $25,594 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $15,871 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $14,207 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $13,989 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $12,933 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $10,243 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,669 |
| Pirfenidone | 12 | $8,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $328 | $115,684164 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $236 | $56,31382 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $129 | $51,70291 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Joplin
- Grant PiersonJoplin$138K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.